Current therapeutic options targeting bone metastasis in metastatic castration resistant prostate cancer.
Prostate cancer is a major public health problem worldwide, still remaining the most common cancer among elder males in both Europe and USA, being responsible for approximately 30,000 deaths in USA in 2014. Nowadays, after decades of basic research, novel treatment options have emerged focusing on men suffering from metastatic castration-resistant prostate cancer improving overall survival. It is also estimated that more than 90% of such patients develop bone metastasis, resulting in a significant increase in morbidity and mortality. The purpose of this review was to discuss the treatment options targeting bone metastasis in castration-resistant prostate cancer patients by examining the available literature focusing primarily in the role of zoledronic acid, denosumab and radium 223.
Department of Urology, General Hospital of Athens G.N.A "G. Gennimatas", Athens, Greece.
Charalampos
C
Fragkoulis
Ioannis
I
Gkialas
Georgios
G
Papadopoulos
Konstantinos
K
Ntoumas
D001859:Bone Neoplasms / Q000188:drug therapy* / Q000473:pathology / Q000532:radiotherapy*; D000069448:Denosumab / Q000627:therapeutic use; D004164:Diphosphonates / Q000627:therapeutic use; D006801:Humans; D007093:Imidazoles / Q000627:therapeutic use; D008297:Male; D064129:Prostatic Neoplasms, Castration-Resistant / Q000473:pathology*; D011868:Radioisotopes / Q000627:therapeutic use; D011883:Radium / Q000627:therapeutic use; D000077211:Zoledronic Acid
D004164:Diphosphonates; D007093:Imidazoles; D011868:Radioisotopes; D000069448:Denosumab; D000077211:Zoledronic Acid; D011883:Radium